Abbott Laboratories (ABT) said Monday it has reached a settlement with DexCom (DXCM) to resolve all outstanding patent disputes related to continuous glucose monitoring products.
The details of the settlement remain confidential but Abbott said there are no financial payments involved in the agreement.
Abbott also said the settlement would lead to the dismissal of all pending cases in courts and patent offices worldwide. The settlement also included a provision that neither company would litigate patent, trade dress nor design rights disputes for the next 10 years.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。